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166 Poster Session IIimplementation of post HSCT revaccination was well received by
patients. A high proportion of allogeneic and early autologous
HSCT recipients successfully underwent revaccination.470
SUCCESSFUL TECHNOLOGICAL IMPLEMENTATION AT AN INNER CITY
MEDICAL CENTER
Robinson, N.1, Dumercy, D.2, Simon, N.1, Willumsen, S.2, Roberts, S.1,
Barredo, J.2, Kleiner, G.2. 1Jackson Memorial Hospital, Miami, FL;
2University of Miami Miller School of Medicine, Miami, FL.
Computerized order entry offers the potential of reducedmedical
errors arising from prescribing or administration. Our medical cen-
ter has recently rolled out a new computerized system. This system
does not provide chemotherapy specific ordering. The Pediatric
HSCT program at University of Miami/Jackson Holtz Children’s
Hospital has been utilizing a dedicated chemotherapy specific com-
mercially available system for outpatient chemotherapy prescribing
for the last four years. This system is one of the few computerized
systems available specifically for chemotherapy. We have recently
implemented computerized order entry for inpatient HSCT. Stan-
dardized order templates for chemotherapy (TBICY, BUCY,
CampFluMel, etc) were created in an attempt to diminish prescrib-
ing and administration errors. The protocols were flagged for high
alert medications (ganciclovir, neupogen, ATGAM) in an attempt
to diminish administration errors (protocol violations). A nursing
flowsheet and extensive nursing in-servicing was implemented si-
multaneously. Since implementation in the inpatient setting we
have observed significantly fewer deviations. Novel technologies
have the potential to diminish medical errors and improve overall
patient care.PHARMACY ORAL471
AN APREPITANT CONTAINING REGIMEN CONTROLS THE DELAYED
NAUSEA AND VOMITING ASSOCIATED WITH HIGH-DOSE MELPHALAN
FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Bechtel, T.P.1, Crawford, B.S.1, Gordon, S.M.2, Penza, S.3,
Hofmeister, C.3, Benson, D.3, Devine, S.3. 1ArthurG James Cancer Hos-
pital and Richard J Solove Research Institute at The Ohio State University
Medical Center, Columbus, OH; 2Richard L Roudebush VA Medical
Center, Indianapolis, IN; 3Arthur G James Cancer Hospital and Richard
J Solove Research Institute at The Ohio State University Medical Center,
Columbus, OH.
Background: Aprepitant is approved for the prevention of acute
and delayed nausea and vomiting associated with highly emetogenic
chemotherapy. It has not, however, been studied in patients receiv-
ing high-dose melphalan prior to an autologous peripheral blood
stem cell transplantation (PBSCT). Objective: The principal ob-
jective was to determine the ability of an aprepitant containing reg-
imen to prevent delayed vomiting 24–120 hours after the
administration of high-dose melphalan followed by an autologous
PBSCT in patients with multiple myeloma (MM). Methods: The
study period was from days -1 through 13. Eligibilty criteria in-
cluded: age.18 years, diagnosis of MM undergoing an autologous
PBSCT utilizing melphalan as the preparative regimen and serum
aminotransferases and t. bilirubin \2 upper limit of normal.
Twenty-five patients received a melphalan dose of 200 mg/M2
and one received 140 mg/M2 on day -1. Treatment consisted of
aprepitant 125 mg orally d -1 followed by 80 mg orally for 2 days
(days 0 and 11); ondansetron 16 mg orally d -1: dexamethasone
12 mg orally d -1 followed by 8 mg daily orally for 3 days (days
0 to 13) with breakthrough medications as needed. Patients were
evaluated for the frequency of emetic episodes, the need for break-
through antiemeticmedication and themeannausea score in 24hour
increments beginning 24 hours after treatment and continuing until
120 hours. The nausea score was determined using a linear analog
scale (0–10). A complete response was defined as no more than one
emetic episode during the evaluation period. Results: A total of 26
patients (17 male, 9 female) were enrolled in the study. Of these pa-
tients, 25 (96%) were complete responders and 24 (92%) had nodocumented emetic episodes during the study period. One patient
(4%) had 1 emetic episode and 1 patient (4%) had 2 emetic episodes.
Some degree of nausea was reported by 23 of 26 patients and the
mean nausea score for the entire group over the study period was
0.7 (range 0–10). All but 3 patients required some breakthrough an-
tiemetic therapy, primarily with promethazine. When compared
with historical results, the aprepitant containing regimen provided
better control than palonosetron alone, ondansetron alone or on-
dansetron/dexamethasone.Conclusion:This aprepitant containing
regimen appeared to control the delayed nausea/vomiting associ-
ated with high-dose melphalan in the PBSCT setting and has now
become the standard of practice in this group at our institution.472
PRE-TRANSPLANT BUSULFAN TEST DOSE IS A RELIABLE ALTERNATIVE
TO FIRST BUSULFAN IV DOSE FOR PHARMACOKINETICS STUDIES IN AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Beri, R., Chunduri, S., Mactal-Haaf, C., Sweiss, K., Dobogai, L.,
Hurter, B., Shord, S., Peace, D., Rondelli, D. University of Illinois, Chi-
cago, IL.
In this study we tested the efficacy of a test dose of IV busulfan in
targeting blood levels of this drug during the conditioning regimen
prior to an allogeneic hematopoietic stem cell transplant. We ana-
lyzedblood samples of 23patientsundergoing allogeneic hematopoi-
etic stem cell transplantation with a busulfan-based conditioning
regimen. Patients received a test dose of busulfan at 0.8 mg/kg as
a 60 minute intravenous infusion. Serial blood samples were drawn
at eight time points- from 15 minutes before dose to 6 hours after
dose completion. Pharmacokinetics (PK) studies were then per-
formed at the Seattle Cancer Care pharmacokinetics laboratory.
The AUC was determined usingWinNonlin Professional software.
The conditioning dose of busulfan was calculated by multiplying
the test dose in mg/AUC  4800. After the first conditioning dose
of busulfan was administered, the same procedure was repeated to
test busulfan PK. If the busulfan AUC was therapeutic (between
4800 mM*min and 5200 mM*min) then the same dose was continued,
otherwise the third and fourth doses of busulfan were adjusted pro-
portionally.
The test dose of 0.8 mg/kg intravenous did not have any hemato-
logical side effects. The mean historic dose (solely based on weight)
was 3.2 6 0.1 mg/kg and the mean dose based on the test dose was
3.56 0.5 mg/kg (p5 0.02). In 17 patients we also analyzed PK after
the first day of conditioning regimen. AUC values of busulfan calcu-
lated from test dose and from day 1 dose were not different (p 5
0.15). The mean dose of busulfan based on test dose was 3.5 6
0.5 mg/kg while the final dose based on day 1 busulfan PK was
3.66 0.7 mg/kg (p5 0.9). Two CML patients who were on dasati-
nib and nilotinib had unusually high AUCs of 6065 and 5920
mM*min respectively suggesting a possible drug interacation be-
tween busulfan and tyrosine kinase inhibitors. Our study suggests
that pre-transplant busulfan test dose reliably predicts the actual
conditioning dose and can be safely utilized to target desirable AUC.
Test dose of busulfan can be conveniently performed anytime be-
fore transplant and therefore can safely replace the first dose PK at
centers where quick busulfan assay cannot be performed.473
RABBIT ATG (THYMOGLOBULIN R) PHARMACOKINETICS IN PEDIATRIC
PATIENTS RECEIVING AMATCHEDUNRELATED DONOR BONEMARROW
TRANSPLANTATION
Call, S.K., Kasow, K., Barfield, R., Leung,W., Madden, R., Horwitz, E.,
Woodard, P., Yusuf, U., Panetta, J.C., Baker, S., Handgretinger, R.,
Rodman, J., Hale, G.A. St. Jude Children’s Research Hospital, Memphis,
TN.
Objective:The pharmacokinetics of active and total rabbit ATG
(rATG) were determined in children with hematologic malignan-
cies receiving a matched unrelated donor (MUD) bone marrow
transplantation (BMT). Methods: 13 pediatric patients (n 5 13)
undergoing MUDHSCTwith a non T-cell depleted graft received
a conditioning regimen of 12 Gy TBI, thiotepa (5 mg/kg q12h  2
doses day-4) and cyclophosphamide (60 mg/kg  2 days -3, -2).
GVHD prophylaxis consisted of cyclosporine and methotraxate.
Poster Session II 167All patients received 1 mg/kg rATG on day -4, then 3 mg/kg/day of
days -3,-2,-1 (total dose 10mg/kg). Blood samples (n5 14) were ob-
tained from each patient at baseline, 24 hrs post each dose, days
0,11,13,15,17 and weeks 2,4,8,12 and 24. Total rATG by ELISA
and active rATGby FACSwere assayed at each time point.Results:
The intersubject variability in Total CL was 50%CV (or 5 range)
and for Active Cl was 70% CV (or 11 range). Total rATG was
measurable in all patients through week 4 and in 11/13 patients at
week 8. Mean day 0 total rATG was 53 mcg/ml (range 22.6–80.7)
and on day 28 was 15.9 mcg/ml (range 5.1–20.6). Active rATG
was measurable in all patients through week 2, 10/13 patients at
week 4 and was undetectable (\0.2 mcg/ml) in 7/13 patients at
week 8. Mean day 0 active rATG was 3.6 mcg/ml (range 0.95–
8.0) and on day 28 was 1.13 mcg/ml (range\0.2–4.64). Median
half-life for total rATG was 27.29 days but could not be reliably es-
timated for active rATG. All patients engrafted by day123 (ANC.
500), and engrafted platelets by day149 (.20K). There were no ep-
isodes of grade 3–4 GVHD; 3 patients developed grade 2 GVHD,
and no grade 3 or 4 adverse rATG related events or serious infec-
tions were observed. Conclusions: When compared to previously
published adult HSCT data and renal transplant data, pediatric pa-
tients have lower total and active rATG levels despite receiving
higher doses. Half lives for total rATG are similar to adult studies.
These data in children suggest differences in initial concentrations
of rATG (total and active) with similar elimination half lives when
compared to adult studies. Differences in patient population,
dose, schedule and sampling make comparisons with prior studies
difficult. Future trials to determine appropriate pediatric doses of
rATG should be performed.474
EVALUATION OF 2 IV BUSULFAN PEDIATRIC DOSING GUIDELINES
Dupuis, L.L.1, Schechter, T.2, Ansari, M.4, Gassas, A.2, Theoret, Y.3,
Champagne, M.A.4, Doyle, J.2. 1The Hospital for Sick Children, Tor-
onto, ON, Canada; 2The Hospital for Sick Children, Toronto, ON, Can-
ada; 3CHU Ste-Justine, Montreal, QC, Canada; 4CHU Ste-Justine,
Montreal, QC, Canada.
Two pediatric dosage guidelines for IV busulfan have been pro-
posed. Nguyen et al (2004) recommend using 5 stratifications based
on actual body weight (\9 kg: 1 mg/kg; 9 to\16 kg: 1.2 mg/kg; 16
to\23 kg: 1.1 mg/kg; 23 to 34 kg: 0.95 mg/kg;.34 kg: 0.8 mg/kg)
while Booth et al (2007) recommend 2 (#12 kg: 1.1 mg/kg;.12 kg:
0.8 mg/kg). This study evaluates the performance of each of these
guidelines by simulating administration of the recommended dose
to children with known busulfan pharmacokinetic parameters.Table 1. Patient’s features and reasons for rejection
Type of SCT planned
Auto-SCT Allo-SCT
Lymphoproli
disorde
n/% Male 157/62% 113/49% 105/63
Median age in
years (range)
49 (10–66) 37.5 (4–64) 46 (18–6
Rejected patients
(%)/Median in months
of time to rejection:
(range)
49 (31%)/4.8
(0.5–13)
24 (21%)/3.2
(0.1–12)
31 (29%)
(0.7–12
Cause of rejection
Progression: n (%) 15 (30.5%) 9 (37.5%) 10 (32%
Insuficient
mobilization:
n (%)
22 (45%) 1 (4%) 13 (42%
Co-morbidity or
death: n (%)
6 (12.5%) 5 (21%) 3 (10%
Patient rejection: n
(%)
5 (10%) 6 (25%) 4 (13%
Other: n (%) 1 (2%) 3 (12.5%) 1 (3%)Health records of children who received IV busulfan prior to
HSCT were reviewed to obtain demographic information, initial
busulfan dose administered, infusion time, and plasma busulfan
concentrations after the initial dose. A minimum of 7 plasma busul-
fan concentrations were available for each patient. Area under the
plasma busulfan concentration vs time curve (AUC) was calculated
using 1-compartmental analysis. Assuming a linear relationship be-
tween dose and AUC, the AUC that would have been achieved after
administration of the busulfan dose indicated by each of the dosage
guidelines was calculated for each child. The proportion of children
who would have achieved an AUC of\900, 900 to 1500 and.1500
mMmin after administration of each of the 2 doses was calculated.
78 children (0.3 to 17.5 years; median: 4.8 years) were included.
Data regarding the AUC achieved after simulated administration
of the proposed busulfan doses are presented below: Neither of
the existing initial IV busulfan pediatric dosing guidelines achieved
an AUC within the target range with sufficient reliability to permit
the use of IV busulfan without determining AUC in each patient.
Under-dosing is more common after administration of doses pro-
posed by Booth et al. Pediatric dosing of IV busulfan requires fur-
ther refinement.Mean AUC AUC\ 900 AUC 5Guidelineferative
rs A
%
5) 4
/4.5
)
19
)
)
)
)mMmin
(±SD)Diag
L/MDS
84/49%
0 (4–64)
(22.5%)/3,7
(0.1–8)
7 (37%)
3 (16%)
4 (21%)
2 (10%)
3 (16%)mMmin
(#;%)nosis
MM
41/49%
56 (32–66)
14 (34%)/6,
(0.5–13.3)
3 (17%)
6 (33.5%)
1 (5.5%)
4 (22%)
0900–1500
mMmin (#;%)Solid
tumors
18/83%
28 (8–48)
3 6 (33%)/2
(0.7–7,5)
4 (66%)
1 (17%)
1 (17%)
0
0AUC . 1500
mMmin (#;%)Booth 2007 1075 ± 336 27* (35) 41 (53) 10 (13)Nguyen 2004 1173 ± 307 14* (18) 50 (64) 14 (18)*p # 0.05.CLINICAL RESEARCH ASSOCIATE – DATA
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WHY ARE SOME STEM CELL TRANSPLANT CANDIDATES (SCT) NOT FI-
NALLY TRANSPLANTED? THE EXPERIENCE OF A SCT TEAM USING AN
ELECTRONIC TOOL TO MANAGE THE TRANSPLANT SCHEDULE
Balsalobre, P., Bun˜o, I., Gayoso, J., Serrano, D., Mun˜oz, C., Gomez-
Pineda, A., Diez-Martin, J.L. Hosp. Gen. Univ. Gregorio Maran˜on,
Madrid, Spain.Other
22/45.5%
32 (20–56)
3 (13.5%)/1
(0.6–1.4)
0
0
2 (66.5%)
1 (33.5%)
0
